According to Zacks, “X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. “
Several other analysts have also recently weighed in on XFOR. ValuEngine cut shares of X4 Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Cowen restated a “buy” rating on shares of X4 Pharmaceuticals in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $27.00.
X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.18). On average, analysts predict that X4 Pharmaceuticals will post -4.77 earnings per share for the current year.
Large investors have recently modified their holdings of the stock. Strs Ohio raised its position in X4 Pharmaceuticals by 779.6% in the 2nd quarter. Strs Ohio now owns 1,900 shares of the company’s stock worth $28,000 after purchasing an additional 1,684 shares during the period. JPMorgan Chase & Co. raised its position in X4 Pharmaceuticals by 767.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,918 shares of the company’s stock worth $30,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC raised its position in X4 Pharmaceuticals by 343.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,994 shares of the company’s stock worth $30,000 after purchasing an additional 1,544 shares during the period. Morgan Stanley raised its position in X4 Pharmaceuticals by 584.0% in the 2nd quarter. Morgan Stanley now owns 3,379 shares of the company’s stock worth $50,000 after purchasing an additional 2,885 shares during the period. Finally, Wells Fargo & Company MN raised its position in X4 Pharmaceuticals by 2,456.9% in the 2nd quarter. Wells Fargo & Company MN now owns 11,327 shares of the company’s stock worth $170,000 after purchasing an additional 10,884 shares during the period. Institutional investors own 61.10% of the company’s stock.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
See Also: High-Yield Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.